Skip to main content

Amyotropic Lateral Sclerosis (ALS) clinical trials at UC Irvine

9 in progress, 5 open to eligible people

Showing trials for
  • An Efficacy and Safety Study of Ravulizumab in ALS Participants

    open to eligible people ages 18 years and up

    The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.

    Orange, California and other locations

  • Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

    open to eligible people ages 18-80

    A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

    Orange, California and other locations

  • Multiple Doses of AT-1501-A201 in Adults With ALS

    open to eligible people ages 18 years and up

    This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40LG. Approximately 54 adults with ALS will be enrolled into the study in the United States at up to 12 ALS treatment sites. Participants will be enrolled into one of four ascending doses.

    Orange, California and other locations

  • Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

    open to eligible people ages 18 years and up

    REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.

    Orange, California and other locations

  • Therapy in Amyotrophic Lateral Sclerosis (TAME)

    open to eligible people ages 18-85

    The purpose of this study is to determine if memantine at 20 mg BID when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA-OPD

    Irvine, California and other locations

  • Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

    Sorry, not accepting new patients

    Expanded Access for treatment with investigational product MSC-NTF cells(NurOwn®) for participants who completed all scheduled treatments and follow-up assessments in BCT-002-US study

    Irvine, California and other locations

  • Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

    Sorry, in progress, not accepting new patients

    A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS)who have completed the ORARIALS-01 trial.

    Orange, California and other locations

  • HEALEY ALS Platform Trial - Master Protocol

    Sorry, not currently recruiting here

    The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

    Orange, California and other locations

  • Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

    Sorry, in progress, not accepting new patients

    This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow, propagated ex vivo and induced to secrete Neurotrophic factors (NTFs). The autologous NurOwn® (MSC-NTF cells) are back-transplanted into the patient intrathecally by standard lumbar puncture where neurons and glial cells are expected to take up the neurotrophic factors secreted by the transplanted cells

    Irvine, California and other locations

Last updated: